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Custo direto médico-hospitalar de 
recaída em esquizofrenia em serviços 
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ABSTRACT
OBJECTIVE: To assess direct medical costs associated with schizophrenia 
relapses in mental health services.
METHODS: The study was conducted in three health facilities in the city 
of São Paulo: a public state hospital; a Brazilian National Health System 
(SUS)-contracted hospital; and a community mental health center. Medical 
records of 90 patients with schizophrenia who received care in 2006 were 
reviewed. Information on inpatient expenditures was collected and used for 
cost estimates.
RESULTS: Mean direct medical cost of schizophrenia relapses per patient 
was US$ 4,083.50 (R$ 8,167.58) in the public state hospital; US$ 2,302.76 
(R$ 4,605.46) in the community mental health center; and US$ 1,198.50 
(R$ 2,397.74) in the SUS-affi liated hospital. The main component was daily 
inpatient room rates (87% - 98%). Medication costs varied depending on the 
use of typical or atypical antipsychotic drugs. Atypical antipsychotic drugs 
were more often used in the community mental health center.
CONCLUSIONS: Costs associated with schizophrenia relapses support 
investments in antipsychotic drugs and strategies to reduce disease relapse and 
the need for mental health inpatient services. Treating patients in a community 
mental health center was associated with medium costs and added the benefi t 
of not depriving these patients from family life.
DESCRIPTORS: Schizophrenia, economics. Recurrence. Direct Service 
Costs. Health Care Costs. Mental Health Services.
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The mean incidence of schizophrenia is one to two cases 
per 10,000 people per year and its prevalence is 0.7% 
in adults worldwide.17 In Brazil, the literature shows 
inconsistent data, but schizophrenia prevalence is likely 
higher than that reported, and close to that reported in a 
meta-analysis by McGrath et al.18,23 Schizophrenia has a 
chronic course with an estimated improvement of 40% 
after fi ve to six years of follow-up.7
To assess schizophrenia burden, Knapp et al (2004) 
reviewed 62 studies and found three major studies on 
costs associated to schizophrenia from the United States, 
Canada, and England.10 The US study estimated a total 
cost of US$ 62.7 billion in 2002, of which US$ 22.7 
billion in direct costs; US$ 7.6 billion in non-medical 
direct costs and US$ 32.4 billion in indirect costs.27 
The Canadian study estimated a cost of schizophrenia 
of C$ 6.5 billion in 2004, of which C$ 2.02 billion 
in direct medical and non-medical costs and C$ 4.83 
billion in indirect costs.5 The English study estimated 
total schizophrenia-related costs in 2004 and 2005 were 
£ 6.7 billion, £ 2 billion in direct and £ 4.7 billion in 
indirect costs.14 In all three studies the main component 
of indirect cost was loss of productivity. According to the 
Global Burden of Disease Assessment, schizophrenia 
causes a high degree of disability and accounts for 1.1% 
of all disability-adjusted life years (DALYs), and for 
2.8% of all years lived with disability (YLDs).26
RESUMO
OBJETIVO: Avaliar o custo direto médico-hospitalar da recaída em 
esquizofrenia, em serviços em saúde mental.
MÉTODOS: Estudo conduzido em três serviços de saúde da cidade de São 
Paulo: um hospital público estadual, um hospital contratado conveniado ao 
Sistema Único de Saúde e um centro de atenção psicossocial. Foram analisados 
90 prontuários de pacientes portadores de esquizofrenia atendidos durante o 
ano de 2006. Os recursos utilizados durante a permanência dos pacientes nos 
serviços foram obtidos e valorados para cálculos das estimativas.
RESULTADOS: O custo direto médico-hospitalar médio da recaída em 
esquizofrenia, por paciente, foi de R$ 8.167,58 (US$ 4.083,50) no hospital 
público estadual, R$ 4.605,46 (US$ 2.302,76) no centro de atenção psicossocial 
e de R$ 2.397,74 (US$ 1.198,50) no hospital conveniado. O principal 
componente foi o custo com diárias (87% a 98%). O custo com medicação 
diferiu quanto à utilização de antipsicóticos típicos ou atípicos. O uso de 
atípicos foi maior no centro de atenção psicossocial.
CONCLUSÕES: O investimento em medicações antipsicóticas e em estratégias 
que diminuam a recaída e a necessidade de diárias nos serviços, especialmente 
hospitalares, são justifi cáveis pela proporção dos custos que estas representam. 
Tratar a recaída no centro de atenção psicossocial apresentou um custo 
intermediário, com o benefício de não privar o paciente do convívio familiar.
DESCRITORES: Esquizofrenia, economia. Recidiva. Custos Diretos de 
Serviços. Custos de Cuidados de Saúde. Serviços de Saúde Mental.
INTRODUCTION
In Brazil, Leitão et al12 assessed direct medical-hospital 
burden of schizophrenia in public health services in 
the state of São Paulo, Southeastern Brazil, in 1998 
and found 81.5% of patients with schizophrenia were 
covered by the National Health System (SUS). Of 
these, 3.7% were temporarily admitted to hospitals, 
2.3% were permanently admitted, 23% were treated 
on an outpatient basis and 71% received no regular 
care. Total direct cost burden of schizophrenia was US$ 
191 million, accounting for 2.2% of total health care 
expenditures. Of this amount, 9.8% went to patients 
who did not receive regular care, 11% to outpatient 
care, 30.5% to permanent admissions and 48.7% to 
temporary admissions.12
There are signifi cant differences in resource allocation 
to mental health between developing and developed 
countries. In Brazil, in 2005, federal funds to SUS 
were around US$ 15 billion (US$ 82.7 per capita), of 
which US$ 358 millions (US$ 1.95 per capita) were 
allocated to mental health care. The expenditures on 
mental health were US$ 2.66 per capita in 1995 and 
US$ 1.95 per capita in 2005, a 26.7% reduction. Mental 
health expenditures in relation to the total health budget 
were reduced from 5.8% to 2.3% in Brazil, while in 
England, mental health expenditures were £ 3.38 billion 
in 2002–2003 and increased by 22% in 2005–2006.1,6
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Schizophrenia relapses are directly related to failure 
to comply with treatment.8,22 In fact, this is one of 
the most expensive aspects of the disease. In 2005, 
re-hospitalization costs in the United States resulting 
from treatment noncompliance were US$ 1,479 
million dollars.24,21 A similar study in England showed 
that noncompliance accounted for an almost three-
fold increase in service costs.9 However, there is no 
consensus on the defi nition of relapse in schizophrenia. 
Lader claims that the patient’s condition before disease 
onset, his or her level of functionality before a given 
episode, episode severity, development of new symp-
toms, duration and extent to which symptoms affect 
functioning should all be considered in the event of a 
new episode.11 A Delphi Consensus involving experts 
from the United Kingdom and Ireland did not manage 
to come to a unanimous agreement regarding the defi -
nition of schizophrenia relapse such as recurrence of 
positive symptoms.2,4
The objective of the present study was to assess direct 
medical costs of schizophrenia relapses in mental 
health services.
METHODS
Three mental health services from the city of São Paulo, 
Southeastern Brazil, were selected based on conve-
nience and data accessibility: a public state hospital 
(PH); a SUS-contracted hospital (CH); and a commu-
nity mental health center (CMHC). The differences 
between these three services are type of care provided 
(full admission in hospitals and partial admission in 
CMHC) and funding sources. The PH and CMHC are 
funded by the state while the psychiatric CH has a fee-
for-service contract with the state. The highest costs are 
expected to be seen in the PH.
Relapsed patients were those who required full-time 
hospitalization in any of the study hospitals or who 
were undergoing psychiatric intensive care at the 
CMHC. According to the Brazilian Ministry of Health, 
psychiatric intensive care involves 13 to 25 visits/
month. Inclusion criteria included patients who were 
diagnosed with schizophrenia regardless of subtype 
and treated between January 1 and December 31, 2006. 
CMHC patients were selected from fi rst quarter (2006) 
records since care authorization for high cost/high 
complexity procedures describing the type of treatment 
regimen are fi lled out on a quarterly basis. Exclusion 
criteria included: different admission and release 
diagnoses (90 CH); inconsistencies between admission 
diagnosis recorded in the database and medical chart 
(8 PH, 20 CH, 9 CMHC); associated neurological 
disease (2 PH, 5 CH), hospital stay longer than 90 days 
(6 PH, 27 CH); and hospital stays starting in 2005 and 
extending into 2006 (7 PH, 17 CH). The 90-day limit 
for hospital stay was set to exclude people living in 
the hospital and those admitted for social reasons. For 
CMHC patients we also excluded patients who had 
been hospitalized or dropped out (n = 4), as well as 
those for whom there were no notes in their medical 
records (n = 2) during the study period.
We randomly drew medical records for review as 
follows: 70 medical records from PH (only relapsed 
patients), 226 from CH (only SUS patients, 85% of all), 
and 47 from CMHC. We reviewed 53 medical records 
from PH, 58 from CH and 45 from CMHC until we 
had a total of 30 medical records for each service that 
met all inclusion and exclusion criteria.
We collected the following patient data from medical 
records: socioeconomic condition; clinical status and 
treatment prior to admission to the service; resources 
used by each patient in terms of number of psychiatric, 
psychological and occupational therapy visits; social 
worker and nursing resources used; clinical consulta-
tions; group and family therapy; outside activities; 
home visits; multidisciplinary team meetings; tests 
performed and medication taken. These costs where 
then evaluated along with general and emergency costs 
related to food, cleaning, safety, laundry, maintenance 
and administration.
Resource values were obtained from each service. The 
costs of state-funded standard drugs were obtained from 
Price Registration and State Health Department website. 
For non-standard drugs we used average selling price; 
for medical tests we used the offi cial SUS table. Drug 
cost was taken from the price list submitted by the 
seller, except for atypical psychotropic drug olanzapine 
that was obtained through the government program for 
high-cost drugs. Human resource costs were obtained 
from CMHC. These costs include personnel assigned to 
other locations but included in the CMHC payroll. For 
currency conversion purposes US$ 1 is approximately 
R$ 2.00 (R$ 2.16 on June 30, 2006).
Direct medical costs (DMC) were calculated as 
follows:
DMC = MCM + MCT + MCDR where:
Mean cost of medication (MCM) = Total cost of medication/30 
patients; mean cost of tests (MCT) = Total cost of testing/30 
patients; mean cost of daily rates (MCDR) = (Human 
resource costs per month/total patients/30 days + monthly 
general costs/total patients/30 days + monthly emergency 
costs/total patients/30 days) x mean length of stay in the 
service (days)
Since the study was conducted from the point of view 
of society at large, and because the study period was no 
longer than one year, no discount rate was applied. The 
study was approved to the Research Ethics Committee 
at Universidade Federal de São Paulo (Protocol No. 
1782/06, in 12/15/2006). Patient confi dentiality was 
ensured.
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Table 1. Clinical and sociodemographic characteristics of relapsed schizophrenia patients by type of health care services. City 
of São Paulo, Southeastern Brazil, 2006.
Variable 
PH CMHC CH
n = 30 n = 30 n = 30
n % n % n %
Gender
Male 30 100.0 18 60.0 0 0.0
Female 0 0.0 12 40.0 30 100.0
Skin color
White 22 73.3 24 80.0 20 66.7
Black 7 23.3 2 6.7 4 13.3
Asian 0 0.0 2 6.7 0 0.0
Mixed 1 3.3 2 6.7 6 20.0
Marital status
Single 24 80.0 18 60.0 22 73.4
Divorced 3 10.0 6 20.0 1 3.3
Married 3 10.0 1 3.3 5 16.7
Widow 0 0.0 0 0.0 1 3.3
Unknown 0 0.0 5 16.7 1 3.3
Children
Yes 6 20.0 8 26.7 16 53.3
No 21 70.0 18 60.0 13 43.4
Unknown 3 10.0 4 13.3 1 3.3
Education
Elementary School 13 43.3 16 53.3 10 33.3
High School 9 30.0 10 33.3 3 10.0
Undergraduate 0 0.0 3 10.0 1 3.3
Illiterate 2 6.7 0 0.0 0 0.0
Unknown 6 20.0 1 3.3 16 53.4
Employment status       
Retired 13 43.3 14 46.7 7 23.3
Unemployed 13 43.3 5 16.7 20 66.6
Informal employment 2 6.7 2 6.7 1 3.3
Never worked 1 3.3 2 6.7 0 0.0
Prolonged medical leave 1 3.3 0 0.0 0 0.0
Unknown 0 0.0 7 23.3 2 6.7
Prior outpatient care
Regular 8 26.7 2 6.7 0 0.0
Irregular 13 43.3 1 3.3 21 70.0
Unknown 9 30.0 27 90.0 9 30.0
Other clinical diseases
No 18 60.0 23 76.7 16 53.3
Yes 12 40.0 7 23.3 14 46.7
Age (years)
Mean (SD) Median 36.2 (11.4) 37.0 43.5 (11.7) 45.5 44.4 (11.5) 44.5
Minimum–Maximum 19–60 19–65 19–73
Duration of disease (years)
Mean (SD) Median 15.7 (10.9) 13.5 20.9 (11.1) 20.0 17.8 (11.8) 18.0
Minimum–Maximum 3–42 4–45 2–50
PH: public state hospital;
CH: Brazilian National Health System-contracted hospital; 
CMHC: community mental health center.
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RESULTS
Table 1 shows sociodemographic and clinical status 
of patients. We found similar age profi les in all three 
services: mean age of patients 36.2 years old in PH, 
43.5 in CMHC, and 44.4 in CH patients. Most were 
white and single with no differences among services 
studied. In three services most of patients were out 
of work – unemployed/not active or retired. The PH 
only had beds for male patients and the CH had beds 
for females only; the CMHC served both males and 
females and 60% of its patients were male. Patients in 
the three services studied had chronic schizophrenia 
with mean disorder duration between 15 and 20 years. 
Table 2. Components of direct medical costs used in schizophrenia relapse by type of health care services. City of São Paulo, 
Southeastern Brazil, 2006.
Variable
PH CMHC CH
n=30 n=30 n=30
Length of stay (days)
Mean (SD) 48.2 (17.3) 90.0 (0.0) 49.7 (18.6) 
Median 51.0 90.0 48.5
Minimum–Maximum 18–73 90–90 16–88
No. psychiatric visits
Mean (SD) 16.8 (7.8) 8.3 ( 5.9) 11.9 ( 6.3) 
Median 16.0 8.0 10.0
Minimum–Maximum 3–34 0–27 4–30
No. psychological sessions (individual)
Mean (SD) 3.7 (2.6) 1.4 (3.3) 0.3 ( 1.3)
Median 3.0 0.0 0.0
Minimum–Maximum 0–11 0–12 0–7
No. occupational therapy sessions (individual)
Mean (SD) 2.1 (1.6)
0.0 
0.2 (1.3)
Median 2.0 0.0
Minimum–Maximum 0–7 0–7
No. social worker visits
Mean (SD) 6.2 (2.8)
0.0 
1.8 (1.1)
Median 6.0 2.0
Minimum–Maximum 2–11 0–5
No. group sessions
Mean (SD) 1.9 (2.3) 0.8 (3.2) 6.3 (2.7)
Median 2.0 0.0 6.5
Minimum–Maximum 0–11 0–15 0–12
No. nursing visits
Mean (SD) 100.7 (41.1) 
0.0
31.0 (16.0)
Median 108.0 27.5
Minimum–Maximum 1–161 0–62
No. family care visits
Mean (SD) 2.1 (1.1) 1.5 (3.9) 0.8 (1.2)
Median 2.0 0.0 0.0
Minimum–Maximum 0–5 0–14 0–4
No. team meetings for case discussion
Mean (SD) 6.7 (2.6)
0.0 
0.2 (0.4)
Median 7.0 0.0
Minimum–Maximum 2–11 0–1
PH: public state hospital; CH: Brazilian National Health System-contracted hospital;
MHC: community mental health center.
19Rev Saude Publica 2011;45(1):14-23
There was no record of prior treatment for 90% of 
patients in CMHC, while 43.3% of patients in PH and 
70% in CH had received intermittent prior treatment. 
Concurrent conditions with the relapse episode were 
more frequently seen in the hospitals (40% in PH and 
46.7% in CH) than in the CMHC (23.3%).
The mean length of stay was similar in both hospitals 
(48.2 and 49.7 days in PH and CH, respectively), but 
almost two-fold for CMHC patients included in the 
quarterly authorization for high cost/high complexity 
procedures. The number of psychiatric visits, individual 
therapy, individual occupational therapy, social worker 
and nursing visits are listed in Table 2. We found no 
record of occupational therapy, social worker or nursing 
services in CMHC medical records. Group activities 
were more often found in CH and team meetings to 
discuss cases in PH. Family services such as family 
support provided by the same providers providing care 
to the patient were available in all three services.
The most common typical antipsychotic drug was 
haloperidol (76.7% in PH and 80% in CH) while 50% 
of CMHC patients were on haloperidol decanoate. 
Of atypical antipsychotics, risperidone was the most 
prescribed, followed by olanzapine (Table 3). The 
total amount spent on medication ranged from R$ 
42.93 (US$ 21.46) (CH) to R$ 555.06 (US$ 277.53) 
(CMHC), largely spent on atypical antipsychotic drugs. 
(Tables 4 and 5)
Of costs that make up the daily rate charged per patient, 
human resources costs were higher in the PH (R$ 70.83 
/ US$ 35.41) than in CH and CMHC (R$ 36.32 / US$ 
18.16 and R$ 32.08 / US$ 16.04, respectively). Also, 
general costs per patient per day in the PH were at least 
seven-fold higher compared to CMHC and CH.
The mean annual direct medical costs of schizophrenia 
relapses per patient ranged from R$ 2,397.00 (US$ 
1,198.50) to R$ 8,167.00 (US$ 4,083.50) for patients 
treated in the PH, CMHC or CH.
DISCUSSION
The highest individual mean direct medical costs of 
schizophrenia relapses were seen for patients treated 
in the PH, followed by CMHC and CH. The major cost 
component was daily rate, which was higher in the PH. 
Drug costs varied according to the type of antipsychotic 
drug used. Low-cost typical antipsychotics were most 
often used in the CH and atypical antipsychotics were 
more commonly used in the CMHC.
Table 3. Antipsychotic drug components of direct medical costs used in schizophrenia relapse by type of health care services. 
City of São Paulo, Southeastern Brazil, 2006.
Antipsychotic
PH CMHC CH
n % n % n %
Typical
Clorpromazine 100 mg (tb) 12 40.0 3 10.0 6 20.0
Haloperidol 5 mg (tb) 23 76.7 6 20.0 24 80.0
Haloperidol decanoate (amp) 13 43.3 15 50.0 2 6.7
Levomepromazine 100 mg (tb) 7 23.3 1 3.3 4 13.3
Pipotazine 25 mg (amp) 0 0.0 2 6.7 0 0.0
Tioridazine 100 mg (tb) 0 0.0 1 3.3 0 0.0
Periciazine 4% (amp) 1 3.3 0 0.0 2 6.7
Atypical       
Aripiprazol 10 mg (tb) 0 0.0 0 0.0 0 0.0
Clozapine 100 mg (tb) 1 3.3 2 6.7 0 0.0
Olanzapine 10 mg (tb) 6 20.0 9 30.0 2 6.7
Quetiapine 100 mg (tb) 0 0.0 0 0.0 0 0.0
Risperidone 2 mg (tb) 7 23.3 5 16.7 9 30.0
Ziprazidone 40 mg (tb) 0 0.0 1 3.3 0 0.0
Emergency  
Chlorpromazine 25 mg (amp) 2 6.7 0 0.0 2 6.7
Haloperidol 5 mg (amp) 2 6.7 0 0.0 9 30.0
Levomepromazine (amp) 0 0.0 0 0.0 4 13.3
PH: public state hospital;
CH: Brazilian National Health System-contracted hospital; 
CMHC: community mental health center; tb: tablet; amp: ampule.
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Relapses are often associated with patient failure to 
comply with maintenance treatment, and this risk is 
higher among those with prior history of noncompli-
ance. A recent review by Marcus et al15 found that 
87,000 patients with schizophrenia are admitted to 
hospitals every year in the United States at a cost of 
US$ 806 million; most of these admissions are due to 
failure to comply with outpatient care.15
Regarding the use of resources during schizophrenia 
relapses, we found that, although patients stayed longer 
in the CMHC (90 days, almost twice the stay in the other 
two services), the use of professional/activity resources 
was notably lower. However, this may be explained by 
poor record keeping. Other possible explanation could 
be that community center patients have less severe 
disease compared to other inpatients or that these 
Table 4. Price (in US$) of psychotropic drugs components of direct medical costs in schizophrenia relapse by type of health 
care services. City of São Paulo, Southeastern Brazil, 2006.
Variable
PH CMHC CH
n = 30 n = 30 n = 30
Mood stabilizer    
Mean (SD) 0.71 (0.99) 0.24 (0.69) 2.52 (9.31)
Median 0.00 0.00 0.00
Minimum–maximum 0.00–3.53 0.00–3.07 0.00–44.55
Typical antipsychotics
Mean (SD) 5.19 (7.51) 6.25 (11.18) 5.84 (8.38)
Median 2.02 2.23 2.4
Minimum–maximum 0.00–29.81 0.00–49.76 0.00–14.90
Atypical antipsychotics
Mean (SD) 70.88 (158.50) 268.5 (394.46) 5.01 (11.82)
Median 0.00 3.70 0.00
Minimum–maximum 0.00–634.08 0.00–1287.24 0.00–57.21
Anticholinergics
Mean (SD) 1.53 (1.11) 1.42 (1.96) 2.36 (2.19)
Median 1.22 0.87 2.03
Minimum–maximum 0.00–4.04 0.00–851 0.00–9.39
Antidepressants
Mean (SD) 0.17 (0.96) 0.00 (0.00) 0.29 (1.15)
Median 0.00 0.00 0.00
Minimum–maximum 0.00–5.27 0.00 0.00–6.18
Benzodiazepines
Mean (SD) 0.20 (0.29) 0.15 (028) 0.72 (0.63)
Median 0.00 0.00 0.67
Minimum–maximum 0.00–092 0.00–0.69 0.00–2.01
Injectable antipsychotics (fast action)
Mean (SD) 0.15 (0.71) 0.00 (0.00) 0.67 (1.26)
Median 0.00 0.00 0.00
Minimum–maximum 0.00–3.93 0.00 0.00–4.57
Injectable anticholinergics
Mean (SD) 0.04 (0.11) 0.00 (0.00) 0.22 (0.40)
Median 0.00 0.00 0.00
Minimum–maximum 0.00–0.47 0.00 0.00–1.39
Injectable benzodiazepines
Mean (SD) 0.01(0.06) 0.00 ( 0.00) 0.06(0.17)
Median 0.00 0.00 0.00
Minimum–maximum 0.00–0.24 0.00 0.00–0.74
PH: public state hospital; CH: Brazilian National Health System-contracted hospital; CMHC: community mental health center.
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Table 5. Direct medical costs in schizophrenia relapse by type of health care services. City of São Paulo, Southeastern Brazil, 
2006.
COST (US$)
PH CMHC CH
N = 30 N = 30 N = 30
Medication
Psychotropic drugs
Mean (SD) 78.7 (158.03) 276.94 (390.97) 16.75 (15.56)
Median -96 23.72 8.97
Minimum–maximum 1.39–635.25 1.45–1292.1 1.51–61.34
Injectable psychotropic drugs (immediate action)
Mean (SD) 0.21(0.73)
0.00
0.95(1.60)
Median 0.00 0.00
Minimum–maximum 0.00–3.93 0.00–4.8
Clinical medications
Mean (SD) 7.90(12.35) 0.59(2.01) 3.76(8.46)
Median 1.04 0.00 0.00
Minimum–maximum 0.00 –50.9 0.00 –9.67 0.00 –37.97
Subtotal
Mean (SD) 86.81 (156.64) 277.53 (390.92) 21.46 (19.3)
Median 17.52 23.72 13.06
Minimum–maximum 2.43–635.25 1.45–1292.1 1.67–74.43
Tests
Mean (SD) 14.85 (30.39) 2.72 (9.96) 0.15 (0.81)
Median 0 0 0
Minimum–maximum 0–153.43 0–53.07 0–4.46
Daily ratea
Mean (SD)
3,982.00 
(1,424.50)
2,022.50 (0.00) 1,177.51 (439.64)
Median 4,210.75 2,022.50 1,148.25
Minimum–maximum 1,486.00–6,027.00 2,022.00–2,022.00 379.00–2,083.50
Total direct medical costs
Mean 4083.79 2302.73 1198.87
(SD) (1478.62) (389.52) (445.08)
Median 4361.11 2053.01 1158.68
Minimum–maximum 1489.09–6545.78 2023.93–3314.57 380.73–2106.71
PH: public state hospital; CH: Brazilian National Health System-contracted hospital; CMHC: community mental health center.
a Daily rate (cost of room/day) = cost with RH + general costs + emergency costs. PH: US$ 35.41 + US$ 44.02 + US$ 3.12 =US$ 
82.56. CMHC: US$ 16.04 + US$ 6.43 + US$ 0.005 = US$ 22.47. CH: US$ 18.16$ + US$ 5.50 + U$ 0.01 = U$ 23.67
patients receiving psychiatric intensive treatment were 
not actually experiencing a crisis.
The component that most infl uenced direct medical 
costs was daily rate charged per patient, with signifi cant 
variations between services. One possible explanation 
for these differences would be the effi ciency of public 
versus private management. Another explanation 
would be the fact that SUS pays the CH for a package 
of services rather than per procedure, encouraging the 
CH to keep its costs down. CMHC human resources and 
general expenses were similar to those in the CH, though 
lengths of stay in the former were longer, probably 
because this is not an inpatient situation and therefore 
there is no pressure to release patients. A study showed 
that treatment in a community mental health center is 
less expensive than conventional hospital care and can 
be more benefi cial to the patient’s quality of life.25
Medication was the second largest component of 
direct medical costs in all three mental health services, 
although these costs were much lower than those of 
daily rates in all cases. The main differences are attrib-
uted to the use of typical or atypical antipsychotic drugs 
and they explain varying costs of care found in the three 
services. There is no consensus about the superiority of 
atypical over typical antipsychotic drugs.13
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Consistent with the literature,19 none of the three 
services studied performed a signifi cant number of 
complementary laboratory tests and their associated 
costs were relatively insignifi cant.
The present study has some limitations. We could not 
confi rm the diagnosis of schizophrenia as it requires 
a personal interview with the patient, which was 
not feasible in this type of study. Also, we adopted 
a practical criterion to defi ne schizophrenia relapse. 
It is also possible that the CMHC sample included 
relapsed patients but also non-relapsed patients who 
were institutionalized and remained under psychiatric 
intensive care. The fact that services are for one sex 
only can introduce a sampling bias as there are gender 
differences in schizophrenia prognosis.3 Another limita-
tions are incomplete records, which may underestimate 
resource use and costs, and potential bias in cost spread-
sheets supplied by the services studied, which were not 
audited. In addition, it was diffi cult to obtain certain 
information from the State Health Department such as 
cleaning and food costs and in some cases we had to use 
indirect means to assess costs or approximate costs.
The costs of treating schizophrenia relapses in commu-
nity mental health centers are at a medium level 
between those of state and contracted hospitals, with 
the additional benefi t of not depriving patients of their 
family life. Besides, the use of drugs with fewer poten-
tial side effects (atypical antipsychotic) has a positive 
impact on their quality of life.16
Direct medical costs associated with schizophrenia 
treatment support the investment in strategies that target 
improved treatment compliance and fewer relapses, as 
well as the development of antipsychotic drugs aiming 
at reducing the need for daily care, especially inpatient 
service. In addition, patients with schizophrenia should 
undergo routine medical assessment as they usually 
have concurrent conditions such as weight gain, meta-
bolic syndromes and cardiovascular diseases.20
In conclusion, further prospective studies including 
interviews with patients and their family are needed 
for better estimating non-medical/hospital direct (e.g., 
expenditures with transportation, accommodation) 
and indirect costs (loss of productivity of patients and 
their family).
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